NASDAQ : STML
|Apr 17, 2014
||4:00 PM ET
|Delayed at least 20min., by eSignal.|
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs) as well as the tumor bulk. Among Stemlines drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity including durable complete responses (CRs) and an overall survival (OS) benefit versus historical controls in Phase I/II studies.
Apr 8, 2014
Stemline Therapeutics Announces FDA Acceptance of IND for SL-701, a Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors
Apr 7, 2014
Stemline Therapeutics to Present at the 13th Annual Needham Healthcare Conference
View all »Events & Presentations
There are no upcoming events at this moment.